Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones (Q38777085)

6 September 2017

Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones (English)

1 reference

6 September 2017

Dario Cattaneo

1

1 reference

6 September 2017

Jan-Willem Alffenaar

series ordinal

2

1 reference

6 September 2017

Michael Neely

series ordinal

3

1 reference

6 September 2017

language of work or name

English

0 references

publication date

16 March 2016

1 reference

Expert Opinion on Drug Metabolism & Toxicology

6 September 2017

1 reference

6 September 2017

12

1 reference

6 September 2017

5

1 reference

6 September 2017

533-544

1 reference

The oxazolidinones: past, present, and future.

6 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Oxazolidinone antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Linezolid: effectiveness and safety for approved and off-label indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Update on the safety of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Pharmacological issues of linezolid: an updated critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Pharmacokinetics of linezolid in subjects with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Is it time to revise linezolid doses in peritoneal dialysis patients? A case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Age and sex effects on the pharmacokinetics of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Potential drug interaction between warfarin and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Correlation between serum linezolid concentration and the development of thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Clinical population pharmacokinetics and toxicodynamics of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Pharmacokinetics and tolerance of linezolid for meticillin-resistant Staphylococcus aureus mediastinitis in paediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Use of linezolid in neonatal and pediatric inpatient facilities--results of a retrospective multicenter survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Tedizolid population pharmacokinetics, exposure response, and target attainment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

The clinical relevance of plasma protein binding changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Achieving target voriconazole concentrations more accurately in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1166204

10.1517/17425255.2016.1166204

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference